Compensation award — excluded from discretionary-purchase analysis.
Traded May 4, 2026 · Filed May 6, 2026
Amgen's SVP & CCO sold $400K of Amgen shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$400,451
Shares × reported transaction price
4 days after results of Apr 30, 2026, 92 days before results of Aug 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $323.85 on May 4, 2026, 23% above its 52-week low and 17% below its high, after a 7% drop over the previous 30 trading days
52-week range $262.28 (May 14, 2025) to $388.16 (Feb 27, 2026), 49% of the way up, from 251 adjusted closes. 30 trading days earlier: $347.80 on Mar 20, 2026. Describes the past only, not a forecast
Footnote references dividend reinvestment
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.6% | +1.2% | +0.5% |
| 30 days | +5.6% | +0.5% | +5.1% |
| 90 days | +17.8% | +5.1% | +12.7% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.